Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:36 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Benralizumab in Patients With Eosinophilic Esophagitis
NCT04543409 · AstraZeneca · PHASE3 · terminated · last registry update 2023-11-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints. Given the lack of clear benefit in this patient population, study has been terminated.” | – | Registry record, AstraZeneca |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL5RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-08-29Results posted on the registry: Memorial Sloan Kettering Cancer Center, Benralizumab + fulvestrant or AIs) and PI3K inhibition (alpelisib) (NCT05966584)
- 2024-08-29Also stopped (terminated): Memorial Sloan Kettering Cancer Center, Benralizumab + fulvestrant or AIs) and PI3K inhibition (alpelisib) (NCT05966584)
- 2024-07-22Phase 3 first posted: AstraZeneca, Benralizumab (NCT06512883)
- 2024-06-18Phase 3 first posted: AstraZeneca, Benralizumab (NCT06465485)
- 2024-04-24Results posted on the registry: AstraZeneca, Benralizumab + Placebo (NCT03186209)
- 2024-03-13Results posted on the registry: AstraZeneca, Benralizumab + Placebo and Benralizumab (NCT04612725)
- 2024-03-13Also stopped (terminated): AstraZeneca, Benralizumab + Placebo and Benralizumab (NCT04612725)
- 2024-01-08Also stopped (withdrawn): Charite University, Berlin, Germany, Fasenra Prefilled Syringe (NCT05528913)
- 2023-08-31Also stopped (terminated): AstraZeneca, Benralizumab + Placebo / Benralizumab (NCT04605094)
- 2023-06-27Results posted on the registry: AstraZeneca, Benralizumab + Placebo / Benralizumab (NCT04605094)
- 2023-05-18Results posted on the registry: AstraZeneca, Benralizumab (NCT04305405)
- 2023-01-20Phase 3 first posted: AstraZeneca, Benralizumab + Placebo (NCT05692180)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision